Cargando…

VITT and Second Doses of Covid-19 Vaccine

Detalles Bibliográficos
Autores principales:	Lacy, Joanne, Pavord, Sue, Brown, Kevin E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757567/ https://www.ncbi.nlm.nih.gov/pubmed/34936738 http://dx.doi.org/10.1056/NEJMc2118507

Ejemplares similares

Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022)

Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)
por: Makris, Michael, et al.
Publicado: (2021)

COVID-19 vaccin et VITT
por: Pernod, G.
Publicado: (2021)

Decline in Pathogenic Antibodies over Time in VITT
por: Schönborn, Linda, et al.
Publicado: (2021)

Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
por: Makris, Michael, et al.
Publicado: (2021)

Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources
por: Greinacher, Andreas, et al.
Publicado: (2022)

SARS-CoV-2 Infection in Patients with a History of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

COVID-19 vaccine-induced VITT/TSS in Malaysia
Publicado: (2022)

Letter to editor – observation on the article titled “Vaccine-Induced Thrombotic Thrombocytopenia (VITT): first report from India”
por: Kotwal, Jyoti, et al.
Publicado: (2023)

COVID-19 vaccine efficacy data: solid enough to delay second dose?
por: Robertson, John F R, et al.
Publicado: (2021)

Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines
por: Pavord, Sue, et al.
Publicado: (2023)

VITT REACTION ASSOCIATED WITH JOHNSON & JOHNSON COVID-19 VACCINE
por: AKUNA, MELANIE, et al.
Publicado: (2021)

COVID-19 and VITT: same or different?
por: Arepally, Gowthami M.
Publicado: (2021)

Vaccine-induced immune thrombocytopaenia and thrombosis (VITT) after COVID-19 vaccination
por: Ribeiro, Maria Inês, et al.
Publicado: (2022)

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021)

How important is the second dose of the COVID-19 mRNA vaccine?
por: Liu, Anne Y.
Publicado: (2021)

Vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Warkentin, Theodore E.
Publicado: (2022)

Epidemiology of VITT
por: Pai, Menaka
Publicado: (2022)

Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”
por: Shaker, Marcus S., et al.
Publicado: (2021)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021)

VITT(al) insights into vaccine-related clots
por: Strich, Jeffrey R., et al.
Publicado: (2021)

Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
por: Dix, Caroline, et al.
Publicado: (2022)

Why some people tolerate the second dose of a vaccine but not the first dose
por: Yu, Yihua Bruce, et al.
Publicado: (2022)

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)

Longitudinal Aspects of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family
por: Noyé, Mickaël, et al.
Publicado: (2022)

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
por: Kanack, Adam J., et al.
Publicado: (2022)

Syndrome VITT : le vaccin Janssen également concerné ?
por: Manus, Jean-Marie
Publicado: (2021)

Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Greinacher, Andreas, et al.
Publicado: (2022)

Vaccine-induced thrombosis and thrombocytopenia (VITT); Exploring the unknown
por: Sunder, Ashok, et al.
Publicado: (2022)

Psoriatic arthritis flare-up after a second dose of BNT162b2 COVID-19 mRNA vaccine
por: Watabe, Daisuke, et al.
Publicado: (2022)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Understanding VITT(ual) reality
por: Rauova, Lubica, et al.
Publicado: (2021)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

Venous sinus thrombosis after the second dose of SARS-CoV-2 vaccine administration
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S
por: Huynh, Angela, et al.
Publicado: (2022)

Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_46gvoo0cl5v36l9s31423vsi1a